Liraglutide vs Exenatide for Type 2 Diabetes Treatment Satisfaction
Author Information
Author(s): Wolfgang E. Schmidt, J. S. Christiansen, M. Hammer, M. J. Zychma, J. B. Buse
Primary Institution: Department of Medicine I, St Josef Hospital, Ruhr University of Bochum Medical School
Hypothesis
Does liraglutide improve patient-reported outcomes compared to exenatide in Type 2 diabetes patients?
Conclusion
Patients reported significantly higher treatment satisfaction with liraglutide compared to exenatide.
Supporting Evidence
- Patients reported a change in overall treatment satisfaction score of 4.71 with liraglutide compared to 1.66 with exenatide.
- 91% of patients in the liraglutide group were satisfied with their treatment compared to 82% in the exenatide group.
- Significant improvements in treatment satisfaction were observed across multiple DTSQ items with liraglutide.
Takeaway
This study shows that people with Type 2 diabetes feel happier with their treatment when they use liraglutide instead of exenatide.
Methodology
Patients with Type 2 diabetes were randomized to receive either liraglutide or exenatide for 26 weeks, followed by a 14-week extension phase where all received liraglutide.
Potential Biases
Potential bias due to the open-label nature of the study.
Limitations
The open-label design may introduce bias, and patient-reported outcomes are subjective.
Participant Demographics
Patients aged 18–80 years with Type 2 diabetes, receiving metformin and/or sulphonylurea.
Statistical Information
P-Value
< 0.0001
Confidence Interval
1.73–4.35
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website